Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Gene therapy 3.0? Gene-coding startup launches with $20M

A new biotech is emerging from stealth to develop what its CEO calls "third-generation gene therapy." Founded by former Human Genome Project researcher Joseph Higgins, SalioGen Therapeutics launched Monday with $20 million in Series A funding to advance a gene therapy platform that works by integrating genomic code into the existing genome using a mammalian-derived enzyme, rather than a bacterial or viral vector that underpin the gene therapies and CRISPR/Cas9 gene-editing technologies that came before it. "We can treat any number of genetic diseases, because we put a code in," said CEO Ray Tabibiazar. "CRISPR cuts. This is more of a paste function."
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.